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Abstract
Purpose: To test the extent of variation among nuclear medicine physicians with respect to
staging non-small cell lung cancer with positron emission tomography (PET).
Procedures: Two groups of nuclear medicine physicians with different levels of PETexperience
reviewed 30 PET scans. They were requested to identify and localize suspicious mediastinal
lymph nodes (MLN) using standardized algorithms. Results were compared between the two
groups, between individuals, and with expert reading.
Results: Overall we found good interobserver agreement (kappa 0.65). Experience with PET
translated into a better ability to localize MLN stations (68% vs. 51%, respectively), and
experienced readers appeared to be more familiar with translating PET readings into clinically
useful statements.
Conclusions: Although our results suggest that clinical experience with PET increases
observers_ ability to read and interpret results from PET adequately, there is room for
improvement. Experience with PET does not necessarily improve the accuracy of image
interpretation.




n non-small cell lung cancer (NSCLC), proven ipsi-
(N2) or contralateral (N3) mediastinal lymph node
involvement often precludes cure by surgery. 2-deoxy-2-
[F-18]fluoro-D-glucose-positron emission tomography (FDG-
PET) is used to stage NSCLC patients. The yield of whole-
body PET pertains to typing the primary pulmonary lesion
and on the preoperative identification of distant and lymph
node metastases. Moreover, PET simplifies and improves
lymph node evaluation by setting the indication for biopsy
and improving its yield. Mediastinoscopy is the standard
technique of invasive lymph node staging but the results in
daily practice are quite variable [1]. It has been suggested
that the proportion of tumor-positive procedures increases if Correspondence to: Otto S. Hoekstra; e-mail: os.hoekstra@vumc.nlguided by PET [2, 3]. So far, mediastinoscopy is the most
often used invasive method, but more recently, endoscopic
techniques [like transesophageal ultrasound-guided fine
needle aspiration (EUS-FNA)] have been developed. Because
the mediastinal areas covered by mediastinoscopy and EUS-
FNA are largely complementary, proper localization of
possible malignant nodes is important to assign patients to
the appropriate procedure. FDG-PET criteria of test positivity
for mediastinal lymph node staging are based on recognition
of focally enhanced uptake (Bhot spots^) vs. background,
rather than on quantitative assessment (like the 1-cm short
axis criterion with CT scanning). Results from PET studies
pertaining to its accuracy in mediastinal staging are robust
[4], but as the technique is disseminating, observer variation
and learning curves still need to be documented.
The aim of the present study was to measure the observer
agreement and accuracy vs. expert readings of mediastinal
lymph nodes in NSCLC staging with FDG-PET at various
levels of complexity and as a function of experience.
Materials and Methods
Study Design
We used a set of 30 PET scans from the study by Joshi et al. [5]o f
consecutive patients referred for staging to the Department of
Nuclear Medicine and PET Research of the Vrije University
Medical Centre. To obtain an adequate case mix, we included
scans of patients with a range of mediastinal lymph node sizes at
CT scanning: (1) e10 mm short axis diameter (n=10), (2) 10.1Y15
mm (n=10), and (3)915 mm (n=10). PET scans had been
performed according to the standard protocol in our institution
using a full ring BGO PET scanner (ECAT EXACT HR+, CTI/
Siemens, starting 60 min after 370 MBq
18FDG) [5].
The scans were analyzed by 14 nuclear medicine physicians
who had extensive experience with SPECT but variable expertise
with PET and mediastinal lymph node staging in NSCLC: seven
had no personal experience with PET (the Binexperienced group^),
whereas the others had at least 1 year of experience with PET in
NSCLC patients in their own clinical practice, which comprised
access to mobile PET once every 1 or 2 weeks (the more
Bexperienced group^). On average, the inexperienced group had
reviewed 0Y15 PET scans, each compared to a 100Y150 (with at
least 50% NSCLC) each in the experienced group. Prior to this
study, the observers had been instructed in workshops by two
expert PET readers, a pulmonologist, and a surgeon about the
concepts, principles, and practice of mediastinal staging in NSCLC
by PET and other methods. The results of all observers were
compared to the combined judgment of two expert nuclear
medicine physicians (EFC and OSH), and the latter readings were
used as the gold standard. The expert readers had been working
together in the same university hospital for numerous years and
had a broad experience with PET [6Y8].
We developed a software tool running Matlab 5.3, which
allowed simultaneous visualization of PET images in the axial,
coronal, and sagittal planes (at 5 or 10 mm slice thickness), with
possible cross linking. Each observer was requested to identify and
interpret any abnormal hot spot representing primary tumor or
lymph node, blinded for the results of the other readers. This
software tool was installed on the personal computer of each
observer, and the results were electronically stored for analysis. To
be able to accurately relate the results of different observers, the
coordinates of each hot spot identified by an observer were stored
and linked to the assigned interpretation. Because none of the
observers had worked with this software before, we provided a test
set (derived from the original data set) of three scans to each
observer prior to the study. These three scans comprised 29
separate abnormal mediastinal lymph node localizations and
therefore provided an adequate way to practice working with
Naruke_s map of lymph node localizations (adapted from
Mountain and Dresler) [9]. Observers had knowledge of the
clinical information provided with the original PET scan referral,
except for the mediastinal stage at CT.
Data Acquisition
The observers were asked to interpret abnormal hot spots pertaining
to the primary tumor and lymph nodes in terms of their localization
and likelihood of malignancy using the classification systems shown
in Table 1. The criterion for test positivity was the presence of
focally enhanced uptake vs. background. Furthermore, observers
were asked to formulate a recommendation with respect to the next
management step to the referring clinician (Table 1). In this context,
we instructed them to use the following protocol: (1) recommend
biopsy of mediastinal lymph nodes in case of suspected (hilar or
mediastinal) lymph node involvement and in case of tumors
adjacent to the mediastinum or hilus, (2) recommend thoracotomy
in case of a peripheral primary tumor without suspicious mediastinal
lymph nodes at PET, and (3) recommend an expectative (Bwait and
see^) policy in case PET shows no abnormal uptake in either the
primary site nor in lymph nodes. For the purpose of the present
investigation, they were instructed to ignore possible suspicious
extrathoracic localizations in these management considerations.
Table 1. Classification system of tumor and lymph nodes
Characteristic Classification
Primary tumor






















Management recommendation Invasive lymph node evaluation
Thoracotomy
Expectative policy
aAccording to the map of lymph node definitions by Mountain and Dresler
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Using the individual scores of the observers, we assigned an BN-
stage according to PET^ for each observer and each patient using
the following classification:
1. N0, peripheral primary tumor, no mediastinal hot spot
2. N1, peripheral primary tumor and separate hot spot
considered to be a hilar lymph node
3. N0YN1, primary tumor within hilar area, no separate
mediastinal hot spot
4. N0YN2, primary tumor adjacent to mediastinum, no
separate mediastinal hot spot
5. N2, hot spot compatible with ipsilateral mediastinal
lymph node
6. N3, hot spot compatible with contralateral mediastinal or
clavicular lymph node
Weperformed a more detailedanalysis ofthe nature ofthe errors
in the Bmanagement recommendation^ classification vs. the expert
reading, identifying whether these errors followed the observers_
own interpretation of suspicious lymph node stations or resulted
from true errors (protocol violation). For example, the former
situation occurred if, in case of a peripheral primary tumor, an
observer considered the ipsilateral right lower tracheobronchial
station to be positive at PET, whereas the expert only identified the
primary lesion. The resulting discrepant management recommen-
dations (mediastinoscopy vs. thoracotomy, respectively) directly
flow from these classifications. We coined such an incorrect answer
as a mistake (M). However, if this observer would have advised to
proceed directly to thoracotomy, this was considered a protocol
violation (P).
We also measured how accurately readers could define and
localize suspected mediastinal lymph node stations at PET.
Compatible with known limitations of PET with respect to spatial
resolution and accounting for different levels of clinical relevance,
we accepted the following differences of nodal classifications:
Naruke stations 1 and 2 [left (L)/right (R), respectively], 4R and
10R, 4L and 10L and 5, and 8 and 9 (L/R, respectively). Using this
simplified system, we analyzed whether observers defined and
localized suspected lymph node metastases vs. the expert readings
Bcorrectly,^ Bincorrectly,^ or Bnot at all.^
Statistical Analysis
Statistical analysis was done by SPSS version 13.0 software. To
determine interobserver agreement regarding Bmanagement rec-
ommendation^ and BN-stage,^ and to compare this to expert
readings, we calculated the Kappa coefficients, using AGREE
version 7.2. We used weighted kappa_s for the N-stage analysis.
Furthermore, to detect potential differences between the two
groups of observers with different PET experience with respect
to the nature of the management recommendation errors, and the
classification of separate mediastinal hot spots, we used the
WilcoxonYMannYWhitney test. Statistical significance was set at
pG0.05.
Results
The 30 PET scans comprised a total of 89 locations of
suspected malignancy, according to the gold standard (expert
reading). Thirty-four represented tumor locations, 55 were
lymph nodes (10 hilar, 39 mediastinal, and six supra-
clavicular). According to expert readers, there was a mean
of three sites (primary lesion and lymph nodes) per patient
(range 1Y13). The experts classified (according to Table 1)
82 lesions as Bdefinitely malignant,^ five as Bprobably
malignant,^ and two as Bequivocal.^ In the final analysis,
these Bprobably^ and Bdefinitely^ malignant locations were
classified as malignant. The expert N-stage classifications
included nine BN0,^ three BN1,^ one BN0YN1,^ three
BN0YN2,^ nine BN2,^ and five BN3,^ according to the
definitions mentioned earlier.
Management recommendations were correct in 80% of
cases (86 errors out of 420 recommendations, 42 in the
experienced group and 44 in the inexperienced group). The
accuracy vs. expert reading was moderate (kappa 0.59) at
either level of experience (Table 2). The level of agreement
among inexperienced observers tended to be lower but did
not reach significance. Four scans accounted for a total of
38 errors (44%), while not a single mistake by any observer
was made in eight.
In the group of inexperienced readers, 29 (of 44; 66%) of
the incorrect management recommendations were protocol
violations (type BP^), vs. 17 (of 42; 40%) in the experienced
readers group (p=0.12). On the contrary, errors that directly
flow from reading errors (type BM^) were significantly
more prevalent in the group of experienced readers (25 out
of 42=59%), vs. 15 out of 44 (34%) in the inexperienced
readers group (p=0.03).
Table 2. Interobserver agreement and accuracy as a function of experience with respect to the classification of BN-stage^ and Bmanagement
recommendation^
Inexperienced observers (n=7) Experienced observers (n=7) Overall
Management recommendation
a
Agreement vs. expert 0.60 (0.42Y0.77) 0.58 (0.37Y0.79) 0.59 (0.42Y0.76)
Pair wise agreement 0.48 (0.35Y0.62) 0.56 (0.41Y0.71) 0.50 (0.37Y0.63)
N-stage
b
Agreement vs. expert 0.58 (0.36Y0.80) 0.72 (0.55Y0.88) 0.65 (0.47Y0.83)
Pair wise agreement 0.56 (0.44Y0.68) 0.61 (0.49Y0.74) 0.58 (0.46Y0.69)
aKappa (95% confidence interval)
bWeighted kappa (95% confidence interval)
320 S.A. Smulders, et al.: Interobserver Variation of FDG-PET in Staging NSCLCCommon errors (type BP^, protocol violations) were,
e.g., to recommend Bexpectative policy^ or Bdirectly to
thoracotomy^ in a patient without enhanced PET uptake in
primary tumor and mediastinal lymph nodes. However, the
provided clinical information stated that bronchoalveolar
cell carcinoma had been proven histologically. Therefore,
Bmediastinal lymph node evaluation^ should have been
recommended because the mediastinum in a patient with
adenocarcinoma without FDG uptake of the primary tumor
cannot be reliably evaluated so that histological confirma-
tion of the mediastinum is required.
N-stage classifications were correct in 68% of cases (286
out of 420 assigned N-stages, 138 in the inexperienced group
and 148 in the experienced group). Experienced observers
tended to have a better agreement with the expert reading than
inexperienced ones (weighted kappa_s 0.72 and 0.58, respec-
tively). N-stages were overestimated in 17.4% (16.7% by the
experienced and 18.1% by the inexperienced observers) and
underestimated in 14.5% of cases (12.9 and 16.2%, respec-
tively).The individualscoresofthe observers (Table3)r e v e a l
that errors in either direction were made by most of them.
Because we used three scans to practice on localizing
mediastinal lymph nodes, 27 scans remained with 26
separate lymph node localizations. The detection rate of
individual mediastinal lymph node stations was similar for
inexperienced and experienced observers (71 and 74%,
respectively, Table 4), and the variation within the groups
was also comparable. However, experienced readers were
better at localizing the stations than inexperienced readers
were (correct in 68 vs. 51%, respectively). The most
common mislocalizations (Table 5) were to classify right
tracheobronchial stations (4R) as upper-right paratracheal
(2R), subcarinal (7) as right tracheobronchial (4R), and left
para-esophageal (8/9L) as left tracheobronchial (4L).
Discussion
Observer variation is the Achilles_ heel of diagnostic
imaging [10] and especially of tests that apply visual
interpretation. It is therefore surprising that the clinical
PET literature contains few studies on observer variation
beyond the level of occasional reports on variation between
two observers participating in an accuracy study. The
present study reports on the results of 14 observers stratified
by their experience with PET, and it accounts for several
aspects of the clinical context of NSCLC staging (manage-
ment recommendation, N-stage, nodal stations). We found
that the accuracy (vs. expert reading) was moderate to
Table 3. Details on N-stage (using the classification system described in








INEXP 1 70.0 (21) 20.0 (6)
INEXP 2 56.7 (17) 20.0 (6)
INEXP 3 70.0 (21) 13.3 (4)
INEXP 4 63.3 (19) 23.3 (7)
INEXP 5 66.7 (20) 20.0 (6)
INEXP 6 66.7 (20) 20.0 (6)
INEXP 7 66.7 (20) 10.0 (3)
Total 65.7 (138) 18.1 (38)
Experienced observers
EXP 1 63.3 (19) 30.0 (9)
EXP 2 76.7 (23) 6.7 (2)
EXP 3 73.3 (22) 10.0 (3)
EXP 4 73.3 (22) 20.0 (6)
EXP 5 73.3 (22) 13.3 (4)
EXP 6 73.3 (22) 16.7 (5)
EXP 7 60.0 (18) 20.0 (6)
Total 70.5 (148) 16.7 (35)
aPercentage of N-stages classified correctly vs. expert reading
bPercentage of overestimated N-stages vs. expert reading
Table 4. Accuracy of inexperienced and experienced observers to detect
and localize the 26 mediastinal lymph node stations present according to
the expert reading
Identified [% (n)]




INEXP 1 76.9 (20) 30.0 (6)
INEXP 2 84.6 (22) 63.6 (14)
INEXP 3 61.5 (16) 62.5 (10)
INEXP 4 80.8 (21) 23.8 (5)
INEXP 5 69.2 (18) 55.6 (10)
INEXP 6 65.4 (17) 64.7 (11)
INEXP 7 57.7 (15) 66.7 (10)
Total 70.9% (129) 51.2% (66)
Experienced
observers
EXP 1 76.9 (20) 65.0 (13)
EXP 2 61.5 (16) 81.3 (13)
EXP 3 69.2 (18) 83.3 (15)
EXP 4 73.1 (19) 89.5 (17)
EXP 5 84.6 (22) 77.3 (17)
EXP 6 80.8 (21) 42.9 (9)
EXP 7 69.2 (18) 38.9 (7)
Total 73.6% (134) 67.9% (91)
a Percentage of identified nodal stations vs. expert reading
b Percentage of correctly localized nodal stations vs. expert reading (e.g.,
INEXP 1 identified 20 out of the 26 stations, and 6 out of 20 were localized
correctly)
Table 5. Mediastinal lymph node stations by experienced and inexperi-
enced observers, according to Mountain and Dresler
Expert (CA) Experienced and inexperienced observers
2 R34 L4 R67 8 R8 LS CT
a Missed
2 R (1 R) 4 1 9
37 3 1 3
4 L (5, 10 L) 24 1 14 31
4 R (10 R) 18 1 85 1 1 1 14 19
71 2 1 3 1 5 1 2 5
8 R (9 R) 4 8 1 1
8 L (9 L) 9 1 8 1 9
SC
c 22 1 4 6 3
Mediastinal lymph node stations using the simplified system mentioned in
the BMaterials and Methods^ section regarding the acceptance of different
lymph node classifications, consistent with clinical practice, for expert and
both groups of observers
CA = correct alternative according to simplified system, SC = supra- or
infraclavicular lymph nodes, T = tumor
aObserver identified pertaining mediastinal lymph node as primary or
second primary tumor
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Our results suggest that clinical experience with PET
improves the ability of readers to localize mediastinal hot
spots correctly, and this is relevant with respect to the next
clinical step: i.e., to decide which invasive verification
method should follow and to enhance the yield of such
procedures. Moreover, within the more experienced group,
the agreement of assigning N-stages and management
recommendations tended to be better. Finally, familiarity
with clinical practice and staging protocols for NSCLC
patients may have contributed to fewer inconsistencies in
management recommendations. Our management advice
constructs were designed to account for generally recog-
nized limitations of PET in mediastinal staging.
With slightly different endpoints, the interobserver
agreement of CT reading appears to be similar to what we
have reported for PET: in CT evaluation of mediastinal
lymph node size, Guyatt et al. reported a kappa of 0.61
regarding the presence of any nodes greater than 1 cm on
CT scan [11]. However, agreement in different nodal groups
varied widely, and it appeared to be far more difficult for
the left superior mediastinal nodes. In our study, we found
that some mistakes were made relatively more often
regarding localizing separate lymph nodes (Table 5). With
the increasing clinical methods to verify imaging findings
(transesophageal, transbronchial EUS-FNA, mediastino-
scopy, video-assisted thoracoscopy), the relevance of
interpreting images at the nodal level is growing. PETYCT
helps to improve the yield of PET and CT reading in
patients newly presenting with lung cancer, but also in
restaging after neoadjuvant therapy. Using PETYCT in this
study, instead of PET alone, would probably have been
more clinically relevant. However, we believe that the
errors related to localizing suspicious foci will improve with
PETYCT, but this is not the case for detection and
interpretation errors. Other limitations of our study were
the relative unfamiliarity of the observers with the display
and registration software and, perhaps, the lack of standard-
ized computer screens.
In the Netherlands, the availability of FDG-PET is
rapidly expanding, even in smaller hospitals, and this has
major implications for local nuclear medicine physicians, as
well as for residents. To our knowledge, the duration of
time that is needed before results on PET are adequately
reviewed and interpreted (Bthe learning curve^) by nuclear
medicine physicians is unknown. We had anticipated
striking differences between experienced and inexperienced
readers, but this was not the case. However, there was
obvious room for improvement in the experienced group
and we suggest that optimal performance is not acquired by
experience alone but requires higher levels of direct
feedback [12]. We propose that such feedback could be
achieved efficiently in experimental settings like those
applied in our study. We believe that data sets like that of
the present study should play a key role in the training of
residents because they can learn and demonstrate improving
skills at any time during their training. However, for
example, in the Dutch setting, this requires that residents
should spend more time in such skill labs and less in daily
clinical production.
Conclusion
Emerging alternatives to invasively stage the mediastinum
in NSCLC puts high levels of skill to interpret PET and CT
scans in NSCLC patients. Observer variation of PET in
mediastinal staging appears to be similar to CT reading, as
reported in literature, with obvious room for improvement.
Training of imaging specialists may require higher levels of
feedback, which can more efficiently be obtained in skill
labs using existing databases than are currently achievable
in local daily clinical practice.
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